Tuberculosis and its Treatment: An Overview

被引：39

作者：

Bansal, Ranju ^{[1
]}

Sharma, Deepika ^{[1
]}

Singh, Ranjit ^{[1
]}

机构：

[1] Panjab Univ, Univ Inst Pharmaceut Sci, Sect 14, Chandigarh 160014, India

来源：

MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2018年 / 18卷 / 01期

关键词：

BCG; DOTS; isoniazid; mycobacterium tuberculosis; pyrazinamide; rifampicin; WHO; TB; DELIVERY; IDENTIFICATION; INHIBITION; EFFICACY; AGENTS; DRUGS;

D O I：

10.2174/1389557516666160823160010

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Tuberculosis (TB) is a primordial infectious disease that mainly affects the lungs. M. tuberculosis (Mycobacterium tuberculosis) is the etiological agent of TB and currently more than one-third of the world population is suffering from TB. For the treatment of TB, administration of multiple antibiotics such as isoniazid, rifampicin, pyrazinamide and ethambutol is required for a long period of time to kill bacteria. However, antibiotic resistance is an emerging problem in multiple drug-resistant tuberculosis (MDR-TB) infections. World Health Organization (WHO) has developed a novel strategy called DOTS (directly observed treatment, short-course), in which specific combination of anti-TB drugs is given to control TB. In this review article we have focused on the comprehensive management of TB and have provided the valuable information about first and second line anti-TB drugs, DOTS and novel drug delivery systems to be used against M. tuberculosis. Important aspects related to new anti-TB drugs and vaccines in various stages of clinical development are also covered in this article.

引用

页码：58 / 71

页数：14

共 69 条

[11] THE ENVELOPE OF MYCOBACTERIA [J].

BRENNAN, PJ ;

NIKAIDO, H .

ANNUAL REVIEW OF BIOCHEMISTRY, 1995, 64 :29-63

[12] Health status and quality of life in tuberculosis [J].

Brown, James ;

Capocci, Santino ;

Smith, Colette ;

Morris, Steve ;

Abubakar, Ibrahim ;

Lipman, Marc .

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2015, 32 :68-75

[13] New approaches to filling the gap in tuberculosis drug discovery [J].

Casenghi, Martina ;

Cole, Stewart T. ;

Nathan, Carl F. .

PLOS MEDICINE, 2007, 4 (11) :1722-1725

[14]

Chapple W, 2012, PAN AFR MED J, V12

[15]

Crowley L.V., 2010, INTRO HUMAN DIS PATH, P374

[16] Phase II Dose-Ranging Trial of the Early Bactericidal Activity of PA-824 [J].

Diacon, Andreas H. ;

Dawson, Rodney ;

du Bois, Jeannine ;

Narunsky, Kim ;

Venter, Amour ;

Donald, Peter R. ;

van Niekerk, Christo ;

Erondu, Ngozi ;

Ginsberg, Ann M. ;

Becker, Piet ;

Spigelman, Melvin K. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (06) :3027-3031

[17] Pulmonary drug delivery systems for tuberculosis treatment [J].

Dinh-Duy Pham ;

Fattal, Elias ;

Tsapis, Nicolas .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2015, 478 (02) :517-529

[18] Current Status and Research Strategies in Tuberculosis Drug Development [J].

Dover, Lynn G. ;

Coxon, Geoffrey D. .

JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (18) :6157-6165

[19] Diagnostic standards and classification of tuberculosis in adults and children [J].

Dunlap, NE ;

Bass, J ;

Fujiwara, P ;

Hopewell, P ;

Horsburgh, CR ;

Salfinger, M ;

Simone, PM .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 161 (04) :1376-1395

[20]

Floyd K., 2011, LANCET, V10, P57

← 1 2 3 4 5 6 7 →